Related Experiment Video

Updated: Nov 20, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

251

Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML

Abdullah Ladha1, Gavin Hui2, Edna Cheung3

  • 1Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Leukemia & Lymphoma
|January 25, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

Related Experiment Videos

Last Updated: Nov 20, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

251
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

A Secret-Shopper Study Evaluating Logistic Barriers to Care Among Young Adults with Acute Lymphoblastic Leukemia.

The oncologist·2026

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

The New England journal of medicine·2026

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies.

Cureus·2026

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Experimental hematology & oncology·2026

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients.

Transplantation and cellular therapy·2026

Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia.

Blood cancer discovery·2026

Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)-a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US.

Leukemia & lymphoma·2026

Usefulness of 20-mm incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma: a single-center experience.

Leukemia & lymphoma·2026

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma.

Leukemia & lymphoma·2026

Revisiting invasive fungal infections in acute lymphoblastic leukemia: a systematic review and meta-analysis.

Leukemia & lymphoma·2026

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.

Leukemia & lymphoma·2026

CD74 in hematological malignancies: from MHC chaperone to therapeutic target.

Leukemia & lymphoma·2026

Biologic Switching Strategies for Anti-Tumor Necrosis Factor Alpha Refractory Noninfectious Uveitis:: Systematic Review and Meta-Analysis of Clinical Approach.

Ophthalmology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us